Straits Times Index
3,266.05 +1.52 (+0.05%) Nikkei
38,320.65 +118.28 (+0.31%) Hang Seng
18,538.57 +224.71 (+1.23%) FTSE 100
8,354.05 +40.38 (+0.49%) Bitcoin USD
61,510.43 -1,115.30 (-1.78%) CMC Crypto 200
1,310.72 +16.05 (+1.24%)
Tarsus Pharmaceuticals, Inc. (TARS)
After hours:
| Previous close | 38.03 |
| Open | 37.32 |
| Bid | 37.13 x 100 |
| Ask | 37.52 x 100 |
| Day's range | 36.17 - 38.27 |
| 52-week range | 12.57 - 40.40 |
| Volume | |
| Avg. volume | 696,740 |
| Market cap | 1.411B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.62 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.38 |
ZacksTarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireTarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025 Expanded sales force on-track to be in the field by the end of the third quarter 2024 Strengthened financial position with an approximately $108 million public equity offering and $200 million fi
ZacksDoes Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
The consensus price target hints at a 38.7% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
